Latest Volition News & Updates

See the latest news and media coverage for Volition. We track all announcements, press releases, and industry mentions in real time, all in one place.

Volition

Epigenetic diagnostics company

volition.com

Headquarters: Henderson, United States
Founded year: 2010
Company type: Public company
Number of employees: 70–200
Industry: Biotechnology & Medical Research

Last updated September 25

Latest news about Volition

In short: Volition launched the DETECSEPS sepsis program, validated its biomarkers, repaid $7.5M debt early, and posted H1 2026 results.

Company announcements

September 25 Volition

Volition launches DETECSEPS, a first in the world for sepsis

Launch coinciding with World Sepsis Day, involving Professor Djillali Annane and the consortium.

September 14 Volition

Volition pre-pays $7.5 million promissory note to reduce equity overhang

The company retired the debt early to prevent stock dilution and strengthen its financial position.

August 26 Volition

Volition highlights first-half revenue growth and new collaborations

The company reports 112% H1 revenue growth, advances lung cancer reimbursement plans, announces a Sysmex partnership, and pursues feline lymphoma milestones.

August 26 Volition

Volition announces Nu.Q NETs biomarker clinical validation for sepsis

The organization highlights this breakthrough as a critical step toward improving early patient detection and guiding targeted therapeutic interventions.

Media coverage

September 14 Financial Times

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured...

September 10 BiopharmaWatch

Volition Unveils Early Cancer Detection Breakthrough - VNRX

VolitionRx presents promising early cancer detection results at ESMO MAP, achieving 95% detection rate for stage I and II cancers.

August 27 Yahoo Finance

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching...

August 26 PR Newswire

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update...

Never miss news about Volition

Track Volition and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Volition competitors & trending companies

Browse news for competitors to Volition and other trending companies.